European Monitoring Plans for the Management of Outbreak of JEV(Japanese Encephalitis Virus)

Japanese Encephalitis Virus (JEV) is one of the most important endemic encephalitis in the world especially in Eastern and Southeastern Asia. JEV affects over 50,000 patients and results in 15,000 deaths annually [1]. JEV is the leading cause of viral encephalitis in 14 Asian countries. Approximately, 60% of the world’s population lives at risk in JEV-endemic regions of these countries. JEV is an acute, vector borne, noncontagious, and zoonotic viral infection of the central nervous system transmitted by the bite of infected mosquitoes [2]. JEV is a single stranded RNA virus and belongs to the family Flaviviridae [3]. JEV is transmitted between animals by mosquito species Culex, Anopheles, Mansonia [4]. Humans become infected with JEV coincidentally when living or travelling in close proximity to the enzootic cycle of the virus [4]. Encephalitis was first described in Japan in 1871, followed by outbreaks very few years. In 1924 the disease was named Japanese B encephalitis to distinguish it from von Economo’s encephalitis, or type A encephalitis (encephalitis lethargic); this was probably a form of autoimmune or post-infectious encephalitis, which caused an outbreak from 1916 to 1927.